Table 2 Characteristics of the primary studies included in the meta-analysis
Author | DOP | Country | Period | Design | PE in ART | ART group | PE in NART | NART group |
|---|---|---|---|---|---|---|---|---|
Julie Hoy [42] | 1999 | Australia | 1982–1995 | Cohort | 131 | 1552 | 399 | 7717 |
O.Salha [43] | 1999 | UK | 1992–1997 | Cohort | 13 | 112 | 1 | 112 |
A.Geipel [44] | 2001 | Germany | 1995–1999 | Cohort | 6 | 114 | 11 | 114 |
Anne Lynch [45] | 2002 | USA | 1994–2000 | Cohort | 27 | 198 | 40 | 330 |
Syeda Zaib-un-Nisa [46] | 2003 | Emirates | 1997–2001 | Cohort | 4 | 36 | 4 | 96 |
Pinborg [47] | 2004 | Denmark | 1997 | Cohort | 71 | 870 | 49 | 566 |
Barbara Luke [48] | 2004 | USA | 1990–2002 | Cohort | 25 | 228 | 24 | 725 |
Bengt Kallen [49] | 2005 | Sweden | 1982–2001 | Cohort | 978 | 13,261 | 55,728 | 2,013,633 |
Fiona Thomson [50] | 2005 | Scotland | 1989–1999 | Cohort | 70 | 1437 | 556 | 21,688 |
Sonia Hernandez-Diaz [51] | 2006 | USA & Canada | 1998–2006 | Cohort | 18 | 349 | 115 | 4762 |
Erez [52] | 2006 | Israel | 1988–2002 | Cohort | 51 | 292 | 193 | 2336 |
Prefumo [53] | 2007 | UK | NA | Case Control | 1 | 31 | 1 | 62 |
Apantaku [24] | 2008 | UK | 1999–2004 | Cohort | 6 | 88 | 7 | 88 |
Chen [54] | 2009 | Canada | 2005 | Cohort | 34 | 1357 | 77 | 5190 |
Sun [55] | 2009 | Canada | 2004–2007 | Cohort | 31 | 2118 | 112 | 8420 |
Morcel [56] | 2010 | France | 2001–2005 | Cohort | 12 | 104 | 13 | 173 |
Miyake [57] | 2010 | Japan | 2005–2007 | Cohort | 15 | 20 | 111 | 230 |
Suzuki [58] | 2010 | Japan | 2000–2007 | Cohort | 4 | 64 | 9 | 87 |
Lehnen [28] | 2011 | Germany | 2000–2009 | Cohort | 10 | 74 | 8 | 305 |
Yang [59] | 2011 | Korea | 1995–2008 | Cohort | 9 | 67 | 22 | 143 |
Kuivasaari-Pirinen [60] | 2012 | Finland | 1996–2007 | Cohort | 16 | 255 | 967 | 26,870 |
Bamberg [61] | 2012 | Germany | 1998–2008 | Cohort | 14 | 426 | 24 | 813 |
Lubovnik [62] | 2012 | Slovenia | 1997–2009 | Case Control | 55 | 246 | 126 | 477 |
Sazonova [63] | 2012 | Sweden | 2002–2006 | Cohort | 520 | 11,292 | 15,984 | 571,914 |
Mohammed [64] | 2012 | Qatar | 2002–2011 | Cohort | 27 | 145 | 30 | 175 |
Le Ray [65] | 2012 | France | 2008–2010 | Cohort | 24 | 144 | 9 | 236 |
Emily Werder [66] | 2013 | USA | 2002–2008 | Cohort | 45 | 215 | 62 | 232 |
Sara S. Malchau [67] | 2013 | Denmark | 1995–2010 | Cohort | 1185 | 24,305 | 2519 | 56,022 |
Rocio Revello [68] | 2013 | Italy | 2000–1010 | Cohort | 28 | 88 | 14 | 59 |
Sari Raisanen [69] | 2013 | Finland | 2006–2010 | Cohort | 90 | 5647 | 3138 | 285,357 |
Alex Fong [70] | 2014 | USA | 2009 | Case Control | 29 | 551 | 7487 | 406,334 |
Nathan S. Fox [71] | 2014 | USA | 2005–2012 | Case Control | 61 | 376 | 15 | 137 |
Tandberg [39] | 2014 | Norway | 1967–2009 | Cohort | 5516 | 8549 | 24,971 | 493,217 |
Tali Silberstein [72] | 2014 | Israel | NA | Cohort | 113 | 1294 | 7889 | 171,513 |
Cagrı Arıoglu Aydın [23] | 2015 | Istanbul | 2007–2010 | Cohort | 13 | 137 | 46 | 133 |
Anne-Maude Morency [73] | 2015 | Canada | 2000–2013 | Cohort | 39 | 181 | 4 | 49 |
Robert Johnston [27] | 2015 | USA | 2009 | Cohort | 29 | 551 | 7847 | 406,334 |
Malinda S. Lee [74] | 2015 | USA | 2006–2008 | Cohort | 17 | 108 | 176 | 2284 |
Bay [75] | 2016 | Denmark | 1999–2013 | Cohort | 2675 | 30,418 | 37,531 | 896,448 |
DoPierala [76] | 2016 | UK | 1992–2009 | Cohort | 203 | 3188 | 2341 | 52,443 |
Nejdet [77] | 2016 | Sweden | 2003–2012 | Cohort | 1156 | 27,084 | 27,912 | 999,804 |
Zhu [78] | 2016 | China | 2006–2014 | Cohort | 98 | 2641 | 110 | 5282 |
Vikstrom [79] | 2016 | Sweden | 1988–2012 | Case Control | 607 | 10,412 | 822 | 18,624 |
Ben-Yaakov [80] | 2016 | Israel | 1988–2012 | Cohort | 378 | 4153 | 4471 | 95,138 |
Sun [81] | 2016 | China | 2010–2014 | Cohort | 42 | 411 | 54 | 742 |
Valenzuela-Alcaraz [26] | 2016 | Spain | 2004–2010 | Cohort | 6 | 488 | 0 | 200 |
Rizzo [82] | 2016 | Italy | 2007–2014 | Cohort | 17 | 249 | 6 | 260 |
Guilbaud [25] | 2017 | France | 2010–2014 | Cohort | 41 | 303 | 32 | 369 |